

Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system.

Noda Y, Anzai K, Mori A, Kohno M, Shinmei M, Packer L

Biochem Mol Biol Int 1997 Jun 42:1 35-44

Abstract

Free radical scavenging activities of water-soluble extracts from some natural sources, health foods, and antioxidant substances were measured using the JES-FR30 JEOL spectrometer. The objective was to develop a standardized method whereby comparison could be made between the radical scavenging activities of complex mixtures. Scavenging of hydroxyl radical was determined using DMPO.

Activity was calibrated using a standard material, L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate] potassium salt (EPC-K1), an analog of vitamin C and vitamin E which is water soluble and

stable at room temperature. The order of greatest hydroxyl radical scavenging activity was green tea extract, pine bark extract

(Pycnogenol), Ginkgo Biloba extract (EGb 761), a flavonoid blend of several fruit and vegetable extracts (GNLD), and Bio-Normalizer

(Sun-O Corp). Activity was determined after treatment of samples with ascorbic acid oxidase. This treatment revealed the presence

of ascorbate in some natural extracts and commercial preparations. The pine bark extract was the most heat resistant and had

ascorbate-like activity in the preparations. Scavenging of superoxide anion was determined using the spin trap,

5,5-dimethyl-1-pyrroline-N-oxide (DMPO), and analyzed by comparison with a standard curve made with superoxide dismutase.

Comparison of the water solubilized components of natural source antioxidants showed that filtrates fractionated using centrifuge type

Millipore filter tubes (M.W. < 100,000; M.W. < 10,000) also had almost the same SOD-like activity.

Samples were also treated with

ascorbate oxidase or by heating (100 degrees C for 10 min). The order of activity, from greatest to least, was Ginkgo biloba extract

EGb 761, pycnogenol, beta-catechin, tea and BioNormalizer.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Tables**
 10. **Figures**
 11. **Supplementary Materials**
 12. **Notes**
 13. **Abbreviations**
 14. **Conflicts of Interest**
 15. **Acknowledgments**
 16. **Author Contributions**
 17. **Funding**
 18. **Data Availability Statement**
 19. **References**
 20. **Appendix**
 21. **Tables**
 22. **Figures**
 23. **Supplementary Materials**
 24. **Notes**
 25. **Abbreviations**
 26. **Conflicts of Interest**
 27. **Acknowledgments**
 28. **Author Contributions**
 29. **Funding**
 30. **Data Availability Statement**
 31. **References**
 32. **Appendix**
 33. **Tables**
 34. **Figures**
 35. **Supplementary Materials**
 36. **Notes**
 37. **Abbreviations**
 38. **Conflicts of Interest**
 39. **Acknowledgments**
 40. **Author Contributions**
 41. **Funding**
 42. **Data Availability Statement**
 43. **References**
 44. **Appendix**
 45. **Tables**
 46. **Figures**
 47. **Supplementary Materials**
 48. **Notes**
 49. **Abbreviations**
 50. **Conflicts of Interest**
 51. **Acknowledgments**
 52. **Author Contributions**
 53. **Funding**
 54. **Data Availability Statement**
 55. **References**
 56. **Appendix**
 57. **Tables**
 58. **Figures**
 59. **Supplementary Materials**
 60. **Notes**
 61. **Abbreviations**
 62. **Conflicts of Interest**
 63. **Acknowledgments**
 64. **Author Contributions**
 65. **Funding**
 66. **Data Availability Statement**
 67. **References**
 68. **Appendix**
 69. **Tables**
 70. **Figures**
 71. **Supplementary Materials**
 72. **Notes**
 73. **Abbreviations**
 74. **Conflicts of Interest**
 75. **Acknowledgments**
 76. **Author Contributions**
 77. **Funding**
 78. **Data Availability Statement**
 79. **References**
 80. **Appendix**
 81. **Tables**
 82. **Figures**
 83. **Supplementary Materials**
 84. **Notes**
 85. **Abbreviations**
 86. **Conflicts of Interest**
 87. **Acknowledgments**
 88. **Author Contributions**
 89. **Funding**
 90. **Data Availability Statement**
 91. **References**
 92. **Appendix**
 93. **Tables**
 94. **Figures**
 95. **Supplementary Materials**
 96. **Notes**
 97. **Abbreviations**
 98. **Conflicts of Interest**
 99. **Acknowledgments**
 100. **Author Contributions**
 101. **Funding**
 102. **Data Availability Statement**
 103. **References**
 104. **Appendix**
 105. **Tables**
 106. **Figures**
 107. **Supplementary Materials**
 108. **Notes**
 109. **Abbreviations**
 110. **Conflicts of Interest**
 111. **Acknowledgments**
 112. **Author Contributions**
 113. **Funding**
 114. **Data Availability Statement**
 115. **References**
 116. **Appendix**
 117. **Tables**
 118. **Figures**
 119. **Supplementary Materials**
 120. **Notes**
 121. **Abbreviations**
 122. **Conflicts of Interest**
 123. **Acknowledgments**
 124. **Author Contributions**
 125. **Funding**
 126. **Data Availability Statement**
 127. **References**
 128. **Appendix**
 129. **Tables**
 130. **Figures**
 131. **Supplementary Materials**
 132. **Notes**
 133. **Abbreviations**
 134. **Conflicts of Interest**
 135. **Acknowledgments**
 136. **Author Contributions**
 137. **Funding**
 138. **Data Availability Statement**
 139. **References**
 140. **Appendix**
 141. **Tables**
 142. **Figures**
 143. **Supplementary Materials**
 144. **Notes**
 145. **Abbreviations**
 146. **Conflicts of Interest**
 147. **Acknowledgments**
 148. **Author Contributions**
 149. **Funding**
 150. **Data Availability Statement**
 151. **References**
 152. **Appendix**
 153. **Tables**
 154. **Figures**
 155. **Supplementary Materials**
 156. **Notes**
 157. **Abbreviations**
 158. **Conflicts of Interest**
 159. **Acknowledgments**
 160. **Author Contributions**
 161. **Funding**
 162. **Data Availability Statement**
 163. **References**
 164. **Appendix**
 165. **Tables**
 166. **Figures**
 167. **Supplementary Materials**
 168. **Notes**
 169. **Abbreviations**
 170. **Conflicts of Interest**
 171. **Acknowledgments**
 172. **Author Contributions**
 173. **Funding**
 174. **Data Availability Statement**
 175. **References**
 176. **Appendix**
 177. **Tables**
 178. **Figures**
 179. **Supplementary Materials**
 180. **Notes**
 181. **Abbreviations**
 182. **Conflicts of Interest**
 183. **Acknowledgments**
 184. **Author Contributions**
 185. **Funding**
 186. **Data Availability Statement**
 187. **References**
 188. **Appendix**
 189. **Tables**
 190. **Figures**
 191. **Supplementary Materials**
 192. **Notes**
 193. **Abbreviations**
 194. **Conflicts of Interest**
 195. **Acknowledgments**
 196. **Author Contributions**
 197. **Funding**
 198. **Data Availability Statement**
 199. **References**
 200. **Appendix**
 201. **Tables**
 202. **Figures**
 203. **Supplementary Materials**
 204. **Notes**
 205. **Abbreviations**
 206. **Conflicts of Interest**
 207. **Acknowledgments**
 208. **Author Contributions**
 209. **Funding**
 210. **Data Availability Statement**
 211. **References**
 212. **Appendix**
 213. **Tables**
 214. **Figures**
 215. **Supplementary Materials**
 216. **Notes**
 217. **Abbreviations**
 218. **Conflicts of Interest**
 219. **Acknowledgments**
 220. **Author Contributions**
 221. **Funding**
 222. **Data Availability Statement**
 223. **References**
 224. **Appendix**
 225. **Tables**
 226. **Figures**
 227. **Supplementary Materials**
 228. **Notes**
 229. **Abbreviations**
 230. **Conflicts of Interest**
 231. **Acknowledgments**
 232. **Author Contributions**
 233. **Funding**
 234. **Data Availability Statement**
 235. **References**
 236. **Appendix**
 237. **Tables**
 238. **Figures**
 239. **Supplementary Materials**
 240. **Notes**
 241. **Abbreviations**
 242. **Conflicts of Interest**
 243. **Acknowledgments**
 244. **Author Contributions**
 245. **Funding**
 246. **Data Availability Statement**
 24

Signature

JAN 21 2005

PAGE 2/23 * RCVD AT 1/21/2005 11:36:08 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/1 * DNIS:7467465 * CSID:512 853 8801 * DURATION (mm-ss):11-06

Application Serial No. 09/336,920 - Filed June 21, 1999


patents are commonly owned. This agreement runs with any patent granted on the captioned patent application and is binding upon the grantee of such patent, and its or his successors or assigns.

4. In making the above disclaimer, Sun Microsystems, Inc. and OpenTV, Inc. do not disclaim the terminal part of any patent granted on the captioned patent application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of U.S. Patent No. 5,903,816, as presently shortened by any terminal disclaimers, in the event that any of such prior patents later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

5. The undersigned is an attorney of record.

A Fee Authorization form is enclosed to cover the fee for this disclaimer; however, the Commissioner is authorized to charge any additional fees that may be required, or credit any overpayment, to Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C. Deposit Account No. 501505\5180-01106\BNK.

Respectfully submitted,



B. Noel Kivlin
Attorney for Applicants
Reg. No. 33,929

Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.
P.O. Box 398
Austin, TX 78767-0398
(512) 853-8840

Date: 1-21-05

Application Serial No. 09/336,920 - Filed June 21, 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: §
§
Broadwin, et al. §
§
Serial No.: 09/336,920 §
§
Filing Date: June 21, 1999 §
§
For: INTERACTIVE TELEVISION §
SYSTEM AND METHOD §
HAVING ON-DEMAND §
WEB-LIKE NAVIGATIONAL §
CAPABILITIES FOR §
DISPLAYING REQUESTED §
HYPERLINKED WEB-LIKE §
STILL IMAGES ASSOCIATED §
WITH TELEVISION CONTENT §

Examiner: Huynh, Son P.

Group Art No.: 2611

Atty. Dkt. No.: 5180-01106

I hereby certify that this correspondence is being sent via
facsimile to: Facsimile No. 703-872-9306, Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the
date indicated below:

B. Noël Kivlin

Name of Registered Representative

1-21-05
Date

Signature

FEE AUTHORIZATION

JAN 21 2005


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The Commissioner is hereby authorized to charge the following fee to Meyertons, Hood,
Kivlin, Kowert & Goetzel, P.C. Deposit Account Number 50-1505/5180-01106/BNK:

Fee: Terminal Disclaimer
Amount: \$130.00
Attorney Docket No.: 5180-01106

The Commissioner is also authorized to charge any extension fee or other fees, which may
be necessary to the same account number.

Respectfully submitted,



B. Noël Kivlin
Attorney for Applicants
Reg. No. 33,929

Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.
P.O. Box 398
Austin, TX 78767-0398
(512) 853-8840
Date: 1-21-05